- Yesterday, Catalent Inc (NYSE:CTLT) announced to acquire Metrics Contract Services for $475 million.
- Keybanc notes that the deal strengthens CTLT’s oral delivery portfolio and targets rapidly growing biologic applications.
- Metrics produces highly active pharmaceutical ingredients that are very difficult to produce but very potent in small doses.
- “After recent acquisitions and capacity expansion on the cell and gene therapy front, this acquisition will continue to balance CTLT’s portfolio, adding to its newly defined Pharmaceutical & Consumer Health segment, a ~$2.2 billion business that combined its legacy oral segments.” Keybanc analyst wrote
- Some media outlets cited Catalent making a bid for Repligen Corporation (NYSE:RGEN), but Keybanc thinks it seems a stretch.
- The analyst says that a merger of equals seems unlikely with Catalent’s $23 billion market cap and levered balance sheet compared to RGEN’s $14 billion equity value.
- Price Action: CTLT shares closed at $109.94 on Friday.
Kimbell Royalty Acquires Mineral And Royalty Interests From MB Minerals For ~$143.1M; Expected To Be Immediately Accretive To Distributable Cash Flow Per Unit
Targeted oil and gas mineral and royalty interests on approximately 60,000 gross acres concentrated in the Northern Midland Basin
Expected to add approximately 1,901 Boe (6:1) per day
